MRK

This lens didn’t produce a usable output for this run.

Merck’s sales are growing, but sharply higher research spending and a quarterly loss make it too early to judge whether newer products can sustain that growth. I would wait for the upcoming results to show stronger evidence that the pipeline can offset the Keytruda risk.

• •Second-quarter and first-half sales rose versus the comparable 2025 periods. — [getFilingText] Sales $ 16,607   $ 15,806   $ 32,893   $ 31,335
• •Research and development spending increased substantially, making the return on reinvestment an important question. — [getFilingText] Research and development 9,741   4,048   22,333   7,669
• •The latest reported quarter was loss-making despite higher sales. — [DATA] Net Income: $-1,335,000,000.00

While MRK trades at an optically cheap forward P/E of 9.13 with low market beta of 0.22, its 2.31% dividend yield offers insufficient carry against a 4.96% 10-Year Treasury yield. Recent GAAP losses and upcoming earnings amidst the looming 2028 Keytruda patent cliff warrant maintaining a cautious, neutral stance.

• •Subdued yield spread against high risk-free benchmark rates — [DATA] Dividend Yield: 2.31%
• •High benchmark discount rates elevate hurdle rate for equity risk — [DATA] 10-Year Treasury Yield: 4.96%
• •Subdued valuation on forward expectations despite trailing earnings noise — [DATA] P/E (Forward): 9.13